https://proteasome-signals.com..../index.php/extracell
A complete of 142 high-risk young ones tested for respiratory syncytial virus had been contained in the study. From the 35 respiratory syncytial virus-positive verified cases, 20 (57%) had obtained palivizumab versus 82 (77%) through the 107 negative controls. The effectiveness of prophylactic palivizumab ended up being 70% (95% CI, 19%-90%) in preventing confirmed clinical illness and 82% (95% CI, 29%-96%) in preventing hospital
Like
Comment
Share
